Gastric Carcinoma at the Era of Targeted Therapies

Author(s): Johann Dreanic, Marion Dhooge, Elena Sion, Catherine Brezault, Stanislas Chaussade, Romain Coriat.

Journal Name: Current Drug Targets

Volume 17 , Issue 15 , 2016

  Journal Home
Translate in Chinese
Submit Manuscript
Submit Proposal

Graphical Abstract:


Abstract:

Gastric and gastro-esophageal cancers (GC/GEJ) appear as the second cancer-related death worldwide. Diagnosis is made at an advanced stage offering a curative attempt in less than 50% of cases. Despite the improvements of the systemic cytotoxic chemotherapy regimens, the prognosis of patients with metastatic GC/GEJ cancer remains poor. Recent insights in biochemical pathways have permitted to identify potential targets. The extracellular domain of HER2 receptors is implicated in cells’ proliferation and in the anti-apoptotic process occurring in GC/GEJ cancers. Trastuzumab, a monoclonal antibody targeting HER2, in addition to chemotherapy permitted to obtain more than one year of survival in HER2-positive advanced GC/GEJ cancers. Recently, ramucirumab, a humanized monoclonal antibody targeting VEGFR-2 receptor demonstrated its efficacy as a second line treatment for patients with advanced GC/GEJ cancer. These encouraging results have justified evaluating targeted therapies in GC/GEJ cancers. In this review, we summarize targeted therapies that might present clinical efficacy in the treatment of advanced GC/GEJ cancers.

Keywords: Gastric carcinoma, gastric cancer, targeted therapy, anti VEGF, anti EGFR, trastuzumab.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 17
ISSUE: 15
Year: 2016
Page: [1818 - 1826]
Pages: 9
DOI: 10.2174/1389450116666150506111327
Price: $58

Article Metrics

PDF: 26
HTML: 3
EPUB: 1
PRC: 1